CD8A and hepatocellular carcinoma: Increased CD4 (+) CD25 (+) Foxp3 (+) Treg may impair effector function of CD8+ T cells, promote disease progression, and represent a potential prognostic marker and therapeutic target in HBV-associated HCC patients.